"While most of these studies have been conducted in the beginning stages of the clinical evaluation process, we are encouraged by the early results and look forward to seeing further results from ongoing clinical trials." Abstracts accepted for presentation at SITC 2021: DuoBody ® -CD40×4-1BB (GEN1042): DuoBody ® -PD-L1×4-1BB (GEN1046): DuoBody ® -CD3xB7H4 (GEN1047): New Research and Technologies: About DuoBody ® -PD-L1×4-1BB (GEN1046) DuoBody-PD-L1x4-1BB (GEN1046) is a proprietary bispecific antibody, jointly owned by Genmab and BioNTech, created using Genmab's DuoBody technology. It targets PD-L1 and 4-1BB, selected to block the inhibitory PD1/PD-L1 axis and simultaneously conditionally activate essential co-stimulatory activity via 4-1BB using an inert DuoBody antibody format. Two clinical studies ( NCT03917381, NCT04937153 ) in solid tumors are ongoing.